Kidney Stones (Nephrolithiasis) — RepurpOS

Disease overview

Alterations

127

Molecular (A)

100

Clinical (B–E)

Direct drugs

Via biomarker

244

Natural agents

Natural products

Merged ranked

268

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Seeds, Examine.com · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Spontaneous passage without intervention: 70-80% of stones <4 mm; 40-50% of stones 4-6mm; <25% of stones >6mm; recurrence in 50% within 10 years without metabolic assessment and prevention

Best-intervention remission

Alpha-1 blockers (tamsulosin, 0.4mg): facilitate passage 30-45% faster for distal ureteral stones; ESWL: 75-80% stone-free for <2cm renal stones; PCNL: 90%+ stone-free for >2cm stones; dietary and metabolic prevention: 50% recurrence reduction with hydration + diet (STOP-JNKi-like approach)

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Moderate — metabolic evaluation and dietary prevention are highly effective but chronically underperformed after first stone

Primary barrier

practice

Barrier detail: Only 10-20% of first-time kidney stone patients receive a 24-hour urine metabolic evaluation that would guide specific dietary and pharmacological prevention; high fluid intake (>2.5L/day) is evidence-based and free but rarely systematically emphasised; recurrence is highly preventable with appropriate dietary modification

Last SoC change: 2019 — AUA/EAU guidelines updated on 24-hour urine evaluation (recommend for all recurrent stone formers, single stone in high-risk); ESWL vs URS evidence updated; no pharmacological paradigm change; thiazide diuretics and citrate supplementation standard since 1980s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0008171 · ORPHA: ORPHA:244305

Right to Try Relevance

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Kidney Stones may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

Phase 3: 11, Phase 2: 6, Phase 1: 1

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

127

Actionable

Pipeline Compounds (Top 6)

Acetaminophen, Alfuzosin, Doxazosin, Furosemide, Ketorolac, Lanthanum Carbonate

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

Showing 80 of 127 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Acute kidney injury	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Calcium oxalate nephrolithiasis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Chronic kidney disease	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Glomerular sclerosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hypercalciuria	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hyperoxaluria	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Hypocitraturia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Low-molecular-weight proteinuria	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Microscopic hematuria	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nephrocalcinosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nephrolithiasis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Proximal tubulopathy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Renal insufficiency	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Renal tubular atrophy	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Tubulointerstitial fibrosis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Ureteropelvic junction obstruction	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ABCC6 ATP binding cassette subfamily C member 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ABCG2 ATP binding cassette subfamily G member 2 (JR blood group)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1A adrenoceptor alpha 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1B adrenoceptor alpha 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1D adrenoceptor alpha 1D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AGXT alanine--glyoxylate aminotransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AHR aryl hydrocarbon receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AHSG alpha 2-HS glycoprotein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ALPL alkaline phosphatase, biomineralization associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AMPD3 adenosine monophosphate deaminase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AOPEP aminopeptidase O (putative)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AP1S3 adaptor related protein complex 1 subunit sigma 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AQP1 aquaporin 1 (Colton blood group)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARID1B AT-rich interaction domain 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ASCC3 activating signal cointegrator 1 complex subunit 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATP6V1B1 ATPase H+ transporting V1 subunit B1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCAS1 brain enriched myelin associated protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCAS3 BCAS3 microtubule associated cell migration factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CA2 carbonic anhydrase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1C calcium voltage-gated channel subunit alpha1 C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CASR calcium sensing receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD44 CD44 molecule (IN blood group)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CLDN10 claudin 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CLDN14 claudin 14	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CLDN16 claudin 16	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CLDN19 claudin 19	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CPNE3 copine 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CPNE8 copine 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CYP24A1 cytochrome P450 family 24 subfamily A member 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Completion Time	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DGKD diacylglycerol kinase delta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DGKH diacylglycerol kinase eta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FAAH fatty acid amide hydrolase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FTO FTO alpha-ketoglutarate dependent dioxygenase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GATA3 GATA binding protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GCKR glucokinase regulator	Molecular	Gene	—	—	Emerging	Open Targets	Ensembl Open Targets
GIPR gastric inhibitory polypeptide receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRHPR glyoxylate and hydroxypyruvate reductase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIK1 glutamate ionotropic receptor kainate type subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRIK2 glutamate ionotropic receptor kainate type subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HAO1 hydroxyacid oxidase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HBB hemoglobin subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HEG1 heart development protein with EGF like domains 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HIBADH 3-hydroxyisobutyrate dehydrogenase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HLF HLF transcription factor, PAR bZIP family member	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Hemoglobin Drop	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
IDUA alpha-L-iduronidase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Infection parameters	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
KCNK5 potassium two pore domain channel subfamily K member 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KLK1 kallikrein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KLK15 kallikrein related peptidase 15	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
L3MBTL3 L3MBTL histone methyl-lysine binding protein 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LRMDA leucine rich melanocyte differentiation associated	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LRRC37A2 leucine rich repeat containing 37 member A2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Length of Hospital Stay	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
MINDY4 MINDY lysine 48 deubiquitinase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MIPOL1 mirror-image polydactyly 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NHERF1 NHERF family PDZ scaffold protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Number of Participants With Complications	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
OPRM1 opioid receptor mu 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
OXGR1 oxoglutarate receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Operative Time	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
PAQR6 progestin and adipoQ receptor family member 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE3A phosphodiesterase 3A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
ACETAZOLAMIDE		Gene-targeted
ACETAZOLAMIDE	None	Gene-targeted
ADALIMUMAB		Gene-targeted
ALFUZOSIN	inhibitor	Gene-targeted
ALFUZOSIN HYDROCHLORIDE	agonist	Gene-targeted
AMIODARONE HYDROCHLORIDE		Gene-targeted
AMITRIPTYLINE HYDROCHLORIDE	inhibitor	Gene-targeted
AMPHETAMINE	None	Gene-targeted
ANHYDROUS TACROLIMUS		Gene-targeted
ASCORBIC ACID		Gene-targeted
ASENAPINE		Gene-targeted
ASFOTASE ALFA		Gene-targeted
AXITINIB		Gene-targeted
BENZPHETAMINE		Gene-targeted
BETHANIDINE		Gene-targeted
BICALUTAMIDE	None	Gene-targeted
CABERGOLINE	inhibitor	Gene-targeted
CAFFEINE		Gene-targeted
CAPECITABINE		Gene-targeted
CARBACHOL	None	Gene-targeted
CARBOPLATIN		Gene-targeted
CARVEDILOL	inhibitor	Gene-targeted
CARVEDILOL PHOSPHATE	inhibitor	Gene-targeted
CERTOLIZUMAB PEGOL		Gene-targeted
CHLORPROMAZINE		Gene-targeted
CHONDROITIN SULFATES		Gene-targeted
CHORIOGONADOTROPIN ALFA		Gene-targeted
CIPROFLOXACIN	None	Gene-targeted
CISPLATIN		Gene-targeted
CLIOQUINOL		Gene-targeted
CLOMIPRAMINE	inhibitor	Gene-targeted
CLOMIPRAMINE	None	Gene-targeted
CLONIDINE HYDROCHLORIDE	agonist	Gene-targeted
CLOZAPINE	inhibitor	Gene-targeted
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM		Gene-targeted
CYCLOPHOSPHAMIDE ANHYDROUS		Gene-targeted
CYCLOSPORINE	inhibitor	Gene-targeted
CYPROHEPTADINE HYDROCHLORIDE	inhibitor	Gene-targeted
DAPIPRAZOLE	inhibitor	Gene-targeted
DAPIPRAZOLE HYDROCHLORIDE	inhibitor	Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
PRAZOSIN	Small molecule	Approved	Strong	105	1 trials View evidence Registry trials NCT00713739 — Alfuzosin for Medical Expulsion Therapy of Ureteral Stones (UNKNOWN) PHASE3 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ADALIMUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALFUZOSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALFUZOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMIODARONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMITRIPTYLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ASCORBIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASENAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASFOTASE ALFA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BENZPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETHANIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CABERGOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAFFEINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBOPLATIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CARVEDILOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARVEDILOL PHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CERTOLIZUMAB PEGOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORPROMAZINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CHONDROITIN SULFATES Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHORIOGONADOTROPIN ALFA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLIOQUINOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLONIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOZAPINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CYCLOSPORINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CYPROHEPTADINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DAPIPRAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DAPIPRAZOLE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
DASATINIB ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEBRISOQUIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXMEDETOMIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXTROAMPHETAMINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIMETHYL SULFOXIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETAMINOPHEN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALFUZOSIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DOXAZOSIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FUROSEMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
KETOROLAC	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LANTHANUM CARBONATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NIFEDIPINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OXYCODONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PRAZOSIN	Small molecule	Phase III	Moderate	80	1 trials View evidence Registry trials NCT00713739 — Alfuzosin for Medical Expulsion Therapy of Ureteral Stones (UNKNOWN) PHASE3 CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
SILODOSIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TAMSULOSIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUCONAZOLE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ISOPROTERENOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MORPHINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MPC-5971	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RELOXALIASE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOLTERODINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SODIUM BICARBONATE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHLORTHALIDONE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
FEBUXOSTAT	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROCHLOROTHIAZIDE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
POTASSIUM ACETATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
POTASSIUM CITRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
POTASSIUM SODIUM HYDROGEN CITRATE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TRANEXAMIC ACID	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETAZOLAMIDE Repurposing via AQP1	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing via ABCC6	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ADALIMUMAB Repurposing via ALPL	Small molecule	Approved	Strong	95	—	DGIdb	—
ALFUZOSIN Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
ALFUZOSIN HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMIODARONE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
AMITRIPTYLINE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ABCC6	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing via ABCG2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ASCORBIC ACID Repurposing via AQP1	Small molecule	Approved	Strong	95	—	DGIdb	—
ASENAPINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
ASFOTASE ALFA Repurposing via ALPL	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing via ABCG2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BENZPHETAMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
BETHANIDINE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ABCC6	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CABERGOLINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
CAFFEINE Repurposing via AHR	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPECITABINE Repurposing via ABCG2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CARBACHOL Repurposing via ABCC6	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBOPLATIN Repurposing via ABCG2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CARVEDILOL Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
CARVEDILOL PHOSPHATE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CERTOLIZUMAB PEGOL Repurposing via ALPL	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORPROMAZINE Repurposing via ABCG2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CHONDROITIN SULFATES Repurposing via ABCC6	Small molecule	Approved	Strong	95	—	DGIdb	—
CHORIOGONADOTROPIN ALFA Repurposing via ABCG2	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via ABCC6	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing via ARID1B	Small molecule	Approved	Strong	95	—	DGIdb	—
CLIOQUINOL Repurposing via AHR	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOMIPRAMINE Repurposing via ABCC6	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLONIDINE HYDROCHLORIDE Repurposing via ADRA1D	Small molecule	Approved	Strong	95	—	DGIdb	—
CLOZAPINE Repurposing via ABCG2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM Repurposing via AQP1	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOPHOSPHAMIDE ANHYDROUS Repurposing via ABCG2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CYCLOSPORINE Repurposing via ABCG2	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CYPROHEPTADINE HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
DAPIPRAZOLE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	—	DGIdb	—
DAPIPRAZOLE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets

Natural Products

69 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Links
Magnesium Natural product Cochrane review Tea and coffee consumption and pathophysiology related to kidney stone… Cochrane review Effects of non-pharmacological interventions on urinary citrate levels:… Cochrane review https://pubmed.ncbi.nlm.nih.gov/22896859/	Nutraceutical	Approved	Emerging	10	5 trials 3 Cochrane 2 Meta-analysis 14 Trial pubs View evidence Registry trials NCT06819111 — Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention (NOT_YET_RECRUITING) PHASE1 NCT00860093 — Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy (TERMINATED) PHASE2 NCT01329042 — Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis (COMPLETED) PHASE4 NCT04095975 — Effectiveness of Urinary Alkalinizing Agents on Kidney Stone Risk (COMPLETED) PHASE4 NCT06651294 — Efficacy of Neorenal Forte for the Complete Elimination of Residual Fragments (RECRUITING) NA Published literature Cochrane review Tea and coffee consumption and pathophysiology related to kidney stone formation: a systematic review (World journal of urology, 2021) Cochrane review Effects of non-pharmacological interventions on urinary citrate levels: a systematic review and meta-analysis (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2016) Cochrane review Meta-analysis Pharmacotherapy for patients with calcium oxalate stones and abnormal urine chemistry: A systematic review and meta-analysis for the Japanese Clinical Practice Guidelines for the Management of Urinary Stones, Third Edition (International journal of urology : official journal of the Japanese Urological Association, 2025) Meta-analysis Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis (Journal of endourology, 1999) Clinical trial publication Timing of magnesium supplementation in patients with nephrolithiasis: A randomized controlled trial (Clinical nephrology, 2025) Clinical trial publication The effects of drinking bicarbonate-rich mineral water in calcium oxalate stone formers: an open label prospective randomized controlled study in an Asian cohort (International urology and nephrology, 2022) Clinical trial publication Prospective Randomized Evaluation of Idiopathic Hyperoxaluria Treatments (Journal of endourology, 2021) Clinical trial publication A Prospective, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Using an Orally Administered Oxalate Decarboxylase (OxDC) (Kidney360, 2020) Clinical trial publication Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets (American journal of kidney diseases : the official journal of the National Kidney Foundation, 2014) CT.gov search · Cochrane · PubMed	PubChem
Calcium Natural product Cochrane review Thiazide therapy in chronic hypoparathyroidism: effects on hypercalciur… Cochrane review Prevention of Recurrent Nephrolithiasis in Adults and Children : A Syst… Cochrane review https://pubmed.ncbi.nlm.nih.gov/41945680/	Nutraceutical	Approved	Emerging	10	8 trials 31 Cochrane 22 Meta-analysis 93 Trial pubs 56 RCT View evidence Registry trials NCT06992206 — What Lies Beneath the Stone? Metabolic Insights From Composition-Based Analysis of Kidney Stones (COMPLETED) NCT07225764 — CaOx Stone Prevention (RECRUITING) PHASE4 NCT04605055 — The Interplay Between Oxalate, Immunity and Infection (WITHDRAWN) NA NCT05650112 — Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria (UNKNOWN) PHASE1 NCT06330246 — O. Formigenes Colonization in Calcium Oxalate Kidney Stone Disease (RECRUITING) NA NCT05161936 — A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels (TERMINATED) PHASE2 NCT02752841 — The Effect of Vitamin D Repletion on Kidney Stone Risk (TERMINATED) NA NCT06989320 — Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease (RECRUITING) NA Published literature Cochrane review Thiazide therapy in chronic hypoparathyroidism: effects on hypercalciuria and renal function-a systematic review and exploratory meta-analysis (Journal of endocrinological investigation, 2026) Cochrane review Prevention of Recurrent Nephrolithiasis in Adults and Children : A Systematic Review (Annals of internal medicine, 2026) Cochrane review Cochrane review Probiotic and Synbiotic Interventions Targeting Oxalate-Degrading Gut Bacteria for the Prevention of Kidney Stones: A Systematic Review (Cureus, 2025) Cochrane review Thiazide diuretics for preventing calcium oxalate recurrent kidney stones: an updated systematic review, meta-analysis and trial sequential analysis of randomized controlled trials (Minerva urology and nephrology, 2025) Meta-analysis Association Between Ambient Temperature and Urolithiasis: A Systematic Review and Meta-analysis (Current urology reports, 2026) Meta-analysis Pharmacotherapy for patients with calcium oxalate stones and abnormal urine chemistry: A systematic review and meta-analysis for the Japanese Clinical Practice Guidelines for the Management of Urinary Stones, Third Edition (International journal of urology : official journal of the Japanese Urological Association, 2025) Meta-analysis SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025) Meta-analysis Causal effects of modifiable risk factors on kidney stones: a bidirectional mendelian randomization study (BMC medical genomics, 2023) Systematic review The gut-kidney microbiome-oxalate axis in calcium oxalate nephrolithiasis: mechanisms and microbiome-based interventions (Frontiers in cellular and infection microbiology, 2026) Systematic review Effect of parathyroidectomy on stone recurrence in primary hyperparathyroidism : A systematic review (Wiener klinische Wochenschrift, 2026) Systematic review Methodological Variations in 24-Hour Urine Collection for Nephrolithiasis: A Systematic Review of Reporting Practices and Clinical Implications (Journal of endourology, 2026) CT.gov search · Cochrane · PubMed	PubChem
Omega-3 Fatty Acids Natural product Human Study Omega-3 fatty acids prevent the formation of urinary calcium oxalate st…	Nutraceutical	Preclinical	Emerging	10	1 pubs View evidence CT.gov search · Cochrane · PubMed	PubChem
Vitamin C Natural product Clinical trial publication The influence of dietary supplementation with cranberry tablets on the… Human Study Vitamin E has an ameliorative effect on oxidative stress associated wit… Human Study Among healthy postmenopausal women, although calcium with vitamin D sup…	Nutraceutical	Approved	Emerging	10	6 trials 1 Trial pubs View evidence Registry trials NCT06989320 — Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease (RECRUITING) NA NCT04437225 — Renal Metabolism of Glycolate to Oxalate (ACTIVE_NOT_RECRUITING) NA NCT03704350 — Influence of Obesity on Endogenous Oxalate Synthesis (ACTIVE_NOT_RECRUITING) NA NCT05229952 — Assessment of Endogenous Oxalate Synthesis (COMPLETED) NA NCT04603898 — Oxalate Formation From Ascorbic Acid (ACTIVE_NOT_RECRUITING) NA NCT01675362 — Are There Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury? (COMPLETED) PHASE4 Published literature Clinical trial publication The influence of dietary supplementation with cranberry tablets on the urinary risk factors for nephrolithiasis (World journal of urology, 2019) CT.gov search · Cochrane · PubMed	PubChem
Vitamin E Natural product Human Study Vitamin E has an ameliorative effect on oxidative stress associated wit… Human Study Among healthy postmenopausal women, although calcium with vitamin D sup… Human Study Calcium stone-forming patients have lower mean levels of vitamin D and…	Nutraceutical	Approved	Emerging	10	1 trials View evidence Registry trials NCT01675362 — Are There Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury? (COMPLETED) PHASE4 CT.gov search · Cochrane · PubMed	PubChem
Garlic Natural product Animal Study Allicin attenuates calcium oxalate crystal deposition.	Food compound	Preclinical	Emerging	10	1 pubs View evidence CT.gov search · Cochrane · PubMed	PubChem
Potassium Natural product Cochrane review Dietary and lifestyle factors for primary prevention of nephrolithiasis… Cochrane review Medical and dietary interventions for preventing recurrent urinary ston… Cochrane review Evaluation and medical management of kidney stones in children	Nutraceutical	Approved	Emerging	7	8 trials 3 Cochrane 3 Meta-analysis 29 Trial pubs View evidence Registry trials NCT06814834 — The Efficacy of Oral Dissolution Therapy (ODT), Extracorporeal Shock Wave Lithotripsy (ESWL), and Combined ESWL and ODT as Non-Invasive Modalities for Treating Small and Medium-Sized Radiolucent Renal Stones (COMPLETED) NA NCT00004284 — Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria (COMPLETED) PHASE3 NCT03984409 — A Dietary Source of Potassium Citrate to Resolve Hypocitraturia and Aciduria in Patients With Kidney Stones (COMPLETED) NA NCT07162974 — Litholytic Therapy for Coral Urate Nephrolithiasis (COMPLETED) NA NCT06819111 — Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention (NOT_YET_RECRUITING) PHASE1 NCT06118320 — The Effective of Potassium Sodium Hydrogen Citrate in Treating Uric Acid Stones Using Gut Microbiota and Metabolomics. (UNKNOWN) NCT02373384 — The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation (COMPLETED) PHASE4 NCT03836144 — Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria (COMPLETED) Published literature Cochrane review Dietary and lifestyle factors for primary prevention of nephrolithiasis: a systematic review and meta-analysis (BMC nephrology, 2020) Cochrane review Medical and dietary interventions for preventing recurrent urinary stones in children (The Cochrane database of systematic reviews, 2017) Cochrane review Evaluation and medical management of kidney stones in children (The Journal of urology, 2014) Meta-analysis Effect of potassium citrate supplement on stone recurrence before or after lithotripsy: systematic review and meta-analysis (Urolithiasis, 2017) Meta-analysis Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials (European urology, 2009) Systematic review Effect of parathyroidectomy on stone recurrence in primary hyperparathyroidism : A systematic review (Wiener klinische Wochenschrift, 2026) Systematic review Preventing and treating kidney stones: an umbrella review of meta-analyses of non-surgical randomized controlled trials (Minerva urology and nephrology, 2025) Clinical trial publication Comparison potassium sodium hydrogen citrate with sodium bicarbonate in urine alkalization: a prospective crossover-controlled trial (International urology and nephrology, 2023) Clinical trial publication Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study (Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2015) Clinical trial publication In vitro anti-lithogenic activity of lime powder regimen (LPR) and the effect of LPR on urinary risk factors for kidney stone formation in healthy volunteers (Urolithiasis, 2015) Clinical trial publication Dissolution therapy versus shock wave lithotripsy for radiolucent renal stones in children: a prospective study (The Journal of urology, 2014) Clinical trial publication Effects of the association of potassium citrate and agropyrum repens in renal stone treatment: results of a prospective randomized comparison with potassium citrate (Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2012) CT.gov search · Cochrane · PubMed	PubChem
Astragalus Natural product Human In Vitro Selenized astragalus polysaccharide may be a candidate drug for the tre…	TCM herb	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Selenium Natural product Clinical trial publication Efficacy and tolerability of olive oil-based ketogenic diet in children… Clinical trial publication [The effect of hemodialysis on some parameters of the antioxidant syste… Human In Vitro Selenized astragalus polysaccharide may be a candidate drug for the tre…	Nutraceutical	Approved	Emerging	7	1 trials 2 Trial pubs View evidence Registry trials NCT01675362 — Are There Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury? (COMPLETED) PHASE4 Published literature Clinical trial publication Efficacy and tolerability of olive oil-based ketogenic diet in children with drug-resistant epilepsy: A single center experience from Turkey (European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2019) Clinical trial publication [The effect of hemodialysis on some parameters of the antioxidant system in the blood of patients with chronic renal failure] (Annales Academiae Medicae Stetinensis, 2004) CT.gov search · Cochrane · PubMed	PubChem
Melatonin Natural product Animal Study, In Vitro Study Melatonin exerts a protective effect in ameliorating nephrolithiasis. Human Study Among healthy postmenopausal women, although calcium with vitamin D sup…	Nutraceutical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	PubChem
Curcumin Natural product Animal Study Curcumin prevents shock-wave lithotripsy-induced renal injury.	Food compound	Preclinical	Emerging	7	1 trials View evidence Registry trials NCT02404701 — Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk (COMPLETED) NA CT.gov search · Cochrane · PubMed	PubChem
Boswellia Natural product Animal Study Luban has shown a significant improvement in the treatment and preventi…	Botanical	Phase II	Emerging	7	1 trials View evidence Registry trials NCT03924596 — Treatment of Renal Stones With Frankincense (Luban) (UNKNOWN) PHASE1, PHASE2 CT.gov search · Cochrane · PubMed	PubChem
Moringa Natural product Animal Study Moringa oleifera has a preventive and curative effect on calcium oxalat…	Botanical	Preclinical	Emerging	7	1 pubs View evidence CT.gov search · Cochrane · PubMed	—
Lactobacillus Natural product Cochrane review Probiotic and Synbiotic Interventions Targeting Oxalate-Degrading Gut B… Meta-analysis Gut microbiota in patients with kidney stones: a systematic review and… Human Study Lactobacillus casei and Bifidobacterium breve reduce urinary oxalate ex…	Probiotic	Phase II	Emerging	7	1 trials 1 Cochrane 1 Meta-analysis View evidence Registry trials NCT00587041 — Use of Oral Probiotics to Reduce Urinary Oxalate Excretion (COMPLETED) PHASE1, PHASE2 Published literature Cochrane review Probiotic and Synbiotic Interventions Targeting Oxalate-Degrading Gut Bacteria for the Prevention of Kidney Stones: A Systematic Review (Cureus, 2025) Meta-analysis Gut microbiota in patients with kidney stones: a systematic review and meta-analysis (BMC microbiology, 2023) CT.gov search · Cochrane · PubMed	—
Fenugreek Natural product Animal Study Trigonelline prevents kidney stone formation processes.	Botanical	Preclinical	Emerging	7	1 pubs View evidence CT.gov search · Cochrane · PubMed	—
Egcg Natural product Animal Study, In Vitro Study Phaseolus vulgaris L. green bean pod extract demonstrated significant a… Review A review of dietary plants for the prevention and management of kidney…	Food compound	Preclinical	Emerging	7	4 pubs View evidence CT.gov search · Cochrane · PubMed	PubChem
Black Seed Oil Natural product Human Study Blackcurrant juice could support the metaphylaxis and treatment of uric… Review N. sativa and its components are beneficial in prevention and curing of…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	PubChem
Niacin Natural product Human Study Among healthy postmenopausal women, although calcium with vitamin D sup… Human Study Calcium stone-forming patients have lower mean levels of vitamin D and… Human Study Vitamin E has an ameliorative effect on oxidative stress associated wit…	Nutraceutical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	PubChem
Valerian Natural product Review Various herbs may have a therapeutic role in preventing and treating ki…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Nigella Sativa (Aka Black Seed) Natural product Human Study N. sativa is demonstrated to have significant positive effects on disap… Human Study Blackcurrant juice could support the metaphylaxis and treatment of uric… Animal Study Treatment of rats with ethanolic extract of Nigella sativa reduced the…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	—
Hibiscus Sabdariffa Natural product Animal Study A water extract of Hibiscus sabdariffa significantly lowers the deposit… Animal Study Hibiscus sabdariffa and Phyllanthus amaraus inhibit calcium oxalate sto… Review A review of dietary plants for the prevention and management of kidney…	Nutraceutical	Preclinical	Emerging	0	—	—
Lactobacillus Casei Natural product Human Study Lactobacillus casei and Bifidobacterium breve reduce urinary oxalate ex… Animal Study Potential role of Lactobacillus and Bifidobacterium for preventing kidn…	Nutraceutical	Preclinical	Emerging	0	—	—
Sodium Bicarbonate Natural product Human Study Mineral water rich in calcium, magnesium and bicarbonate improves urine… Human Study Mineral waters containing bicarbonate reduce the risk of urinary stone…	Food compound	Preclinical	Emerging	0	—	PubChem
Orange Natural product Human Study Orange juice may have a therapeutic effect in reducing stone-forming ri… Review Role of citrus fruit juices in prevention of kidney stone disease.	Nutraceutical	Preclinical	Emerging	0	—	—
Orthosiphon Natural product Animal Study O. grandiflorum has a significant inhibitory effect on crystal depositi… Animal Study Prophylactic effects of Orthosiphon stamineus extracts on experimental…	Nutraceutical	Preclinical	Emerging	0	—	—
Pomegranate Natural product Animal Study Pomegranate juice has a protective effect on kidney stone formation (ne… Review A review of dietary plants for the prevention and management of kidney…	Nutraceutical	Preclinical	Emerging	0	—	—
Dandelion Natural product In Vitro Study This research indicated that taraxasterol and dandelion extract has ant… Review Various herbs may have a therapeutic role in preventing and treating ki…	Nutraceutical	Preclinical	Emerging	0	—	—
Black Currant Natural product Human Study Blackcurrant juice could support the metaphylaxis and treatment of uric…	Nutraceutical	Preclinical	Emerging	0	—	—
Cranberry Natural product Human Study Blackcurrant juice could support the metaphylaxis and treatment of uric…	Nutraceutical	Preclinical	Emerging	0	—	—
Bifidobacterium Breve Natural product Human Study Lactobacillus casei and Bifidobacterium breve reduce urinary oxalate ex… Animal Study Potential role of Lactobacillus and Bifidobacterium for preventing kidn…	Nutraceutical	Preclinical	Emerging	0	—	—
Lemon Juice Natural product Human Study Lemonade therapy appears to be a reasonable alternative for patients wi… Human Study Blackcurrant juice could support the metaphylaxis and treatment of uric… Human Study Orange juice may have a therapeutic effect in reducing stone-forming ri…	Nutraceutical	Preclinical	Emerging	0	—	—
Ayurvedic Medicine: Kulattha Natural product Human Study The Ayurvedic herb Kulattha is superior to potassium citrate in treatin…	Nutraceutical	Preclinical	Emerging	0	—	—
Sesbania Grandiflora Natural product Human Study The leaf juice of S. grandiflora demonstrates significant antiurolithia…	Nutraceutical	Preclinical	Emerging	0	—	—
Flavonoids Natural product Animal Study, In Vitro Study Hyperoside ameliorates renal tubular oxidative damage and calcium oxala…	Nutraceutical	Preclinical	Emerging	0	—	—
Common Bean Natural product Animal Study, In Vitro Study Phaseolus vulgaris L. green bean pod extract demonstrated significant a…	Nutraceutical	Preclinical	Emerging	0	—	—
Yellow Tea Natural product Animal Study PPARG: A novel target for yellow tea in kidney stone prevention.	Nutraceutical	Preclinical	Emerging	0	—	—
Seaweed Natural product Animal Study Brown seaweed extract demonstrates significant prevention effects on ki…	Nutraceutical	Preclinical	Emerging	0	—	—
Carvacrol Natural product Animal Study Carvacrol reduced pathological and biochemical damage, and improved kid…	Nutraceutical	Preclinical	Emerging	0	—	—
Carnosine Natural product Animal Study Effect of carnosine on the course of experimental urate nephrolithiasis.	Food compound	Preclinical	Emerging	0	—	PubChem
Evening Primrose Oil Natural product Animal Study Evening primrose may have preventive and therapeutic value in infection…	Nutraceutical	Preclinical	Emerging	0	—	—
Phyllanthus Amarus Natural product Animal Study Hibiscus sabdariffa and Phyllanthus amaraus inhibit calcium oxalate sto… Animal Study Phyllanthus niruri inhibits crystal growth in renal stone formation.	Nutraceutical	Preclinical	Emerging	0	—	—
Phyllanthus Niruri (Stonebreaker) Natural product Animal Study Phyllanthus niruri inhibits crystal growth in renal stone formation. Animal Study Hibiscus sabdariffa and Phyllanthus amaraus inhibit calcium oxalate sto…	Nutraceutical	Preclinical	Emerging	0	—	—
Crataeva Nurvala (Varuna) Natural product Animal Study Plantain and crataeva nurvala (Varuna) has therapeutic value in the man…	Nutraceutical	Preclinical	Emerging	0	—	—
Plantain Natural product Animal Study Plantain and crataeva nurvala (Varuna) has therapeutic value in the man…	Nutraceutical	Preclinical	Emerging	0	—	—
Bifidobacterium Longum Natural product Human Study Lactobacillus casei and Bifidobacterium breve reduce urinary oxalate ex… Animal Study Potential role of Lactobacillus and Bifidobacterium for preventing kidn…	Nutraceutical	Preclinical	Emerging	0	—	—
Lactobacillus Plantarum Natural product Human Study Lactobacillus casei and Bifidobacterium breve reduce urinary oxalate ex… Animal Study Potential role of Lactobacillus and Bifidobacterium for preventing kidn…	Nutraceutical	Preclinical	Emerging	0	—	—
Coconut Water Natural product Human Study Mineral water rich in calcium, magnesium and bicarbonate improves urine… Human Study Mineral waters containing bicarbonate reduce the risk of urinary stone… Human Study The consumption of bottled water is associated with heightened risk for…	Nutraceutical	Preclinical	Emerging	0	—	—
Rubia Cordifolia Natural product Animal Study Rubia cordifolia has a protective effect against ethylene glycol induce…	Nutraceutical	Preclinical	Emerging	0	—	—
Caffeic Acid Natural product Animal Study The dietary polyphenol caffeic acid has a protective effect against eth…	Nutraceutical	Preclinical	Emerging	0	—	—
Myrtle Natural product Animal Study The effect of Myrtus communis L. extract on nephrolithiasis model.	Nutraceutical	Preclinical	Emerging	0	—	—
Apigenin Natural product Animal Study The results showed that both apigenin and celery extracts caused kidney…	Food compound	Preclinical	Emerging	0	—	PubChem
Celery Natural product Animal Study The results showed that both apigenin and celery extracts caused kidney…	Nutraceutical	Preclinical	Emerging	0	—	—
Dates Natural product Animal Study The use of aqueous extract of date palm pits has been effective in the…	Nutraceutical	Preclinical	Emerging	0	—	—
Urolithin a Natural product Animal Study Urolithin A protects against calcium oxalate-induced crystal formation…	Nutraceutical	Preclinical	Emerging	0	—	—
Nettle Natural product Review A review of dietary plants for the prevention and management of kidney…	Nutraceutical	Preclinical	Emerging	0	—	—
Oregano Natural product Review A review of dietary plants for the prevention and management of kidney…	Nutraceutical	Preclinical	Emerging	0	—	—
Parsley Natural product Review A review of dietary plants for the prevention and management of kidney…	Nutraceutical	Preclinical	Emerging	0	—	—
Raspberry Natural product Review A review of dietary plants for the prevention and management of kidney…	Nutraceutical	Preclinical	Emerging	0	—	—
Corn Silk Natural product In Vitro Study Carboxymethylation of corn silk polysaccharide and its inhibition on ad…	Nutraceutical	Preclinical	Emerging	0	—	—
Goldenrod Natural product Commentary Goldenrod may provide a safe, inexpensive treatment for urinary tract d…	Nutraceutical	Preclinical	Emerging	0	—	—
Phytate Natural product Review Inositol hexaphosphate inhibits crystallization of calcium salts, and m…	Nutraceutical	Preclinical	Emerging	0	—	—
Grapefruit Natural product Review Role of citrus fruit juices in prevention of kidney stone disease.	Nutraceutical	Preclinical	Emerging	0	—	—
Lemon Natural product Human Study Lemonade therapy appears to be a reasonable alternative for patients wi… Review Role of citrus fruit juices in prevention of kidney stone disease.	Nutraceutical	Preclinical	Emerging	0	—	—
Burdock Natural product Review Various herbs may have a therapeutic role in preventing and treating ki…	Nutraceutical	Preclinical	Emerging	0	—	—
Horsetail Natural product Review Various herbs may have a therapeutic role in preventing and treating ki…	Nutraceutical	Preclinical	Emerging	0	—	—
Lithospermum Officinale Natural product Review Various herbs may have a therapeutic role in preventing and treating ki…	Nutraceutical	Preclinical	Emerging	0	—	—
Silene Saxifraga Natural product Review Various herbs may have a therapeutic role in preventing and treating ki…	Nutraceutical	Preclinical	Emerging	0	—	—
Uva Ursi (Aka Bearberry) Natural product Review Various herbs may have a therapeutic role in preventing and treating ki…	Nutraceutical	Preclinical	Emerging	0	—	—
Watermelon Natural product In Vitro Study Watermelon and demonstrated that pulp extract possessed significant ant…	Nutraceutical	Preclinical	Emerging	0	—	—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.